Analysts Conflicted on These Healthcare Names: Can-Fite BioPharma (CANF), Collegium Pharmaceutical (COLL) and Ironwood Pharma (IRWD)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Can-Fite BioPharma (NYSE:CANF), Collegium Pharmaceutical (NASDAQ:COLL) and Ironwood Pharma (NASDAQ:IRWD).

Can-Fite BioPharma (CANF)

In a report released today, Jason Kolbert from H.C. Wainwright maintained a Buy rating on Can-Fite BioPharma, with a price target of $8. The company’s shares closed yesterday at $1.22, close to its 52-week low of $1.12.

Kolbert commented:

“Our therapeutic models are patient-based and reflect our assumptions for the product launch dates, product attributes, and pricing, to determine the future revenue streams. We apply a probability of success in these models.”

According to TipRanks.com, Kolbert ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.5% and a 37.3% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Keryx Biopharma.

Can-Fite BioPharma has an analyst consensus of Moderate Buy, with a price target consensus of $8.

See today’s analyst top recommended stocks >>

Collegium Pharmaceutical (COLL)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Collegium Pharmaceutical, with a price target of $33. The company’s shares closed yesterday at $16.98.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 19.5% and a 42.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Aurinia Pharmaceuticals.

Currently, the analyst consensus on Collegium Pharmaceutical is a Strong Buy with an average price target of $30.50, implying a 79.6% upside from current levels. In a report issued on August 8, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $35 price target.

.

Ironwood Pharma (IRWD)

H.C. Wainwright analyst Ram Selvaraju reiterated a Sell rating on Ironwood Pharma today and set a price target of $12.50. The company’s shares closed yesterday at $18.37.

Selvaraju observed:

“We utilize a discounted cash flow (DCF)-based approach to value Ironwood shares, which involves a risk-adjusted net present value (rNPV) assessment of each of the company’s commercial and clinical-stage assets.”

According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.5% and a 39.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Ironwood Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $20.88.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts